ASCO 2023 | Head and neck updates at ASCO 2023
Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, provides his highlights in head and neck cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including strategies to overcome EGFR resistance and manage HPV-positive cancers. Dr Saba additionally highlights the need to find new strategies that build upon first line pembrolizumab. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah. I mean, I think it’s it’s the field is really very different and and moving, moving very rapidly. I think the, the first line, recurrent metastatic setting is really going to probably change over the next few years from single agent, pembro or pembrolizumab and chemotherapy because of the novel agents that we mentioned. I think the question of, you know, building on the EGFR resistance with the cetuximab trials is very interesting...
Yeah. I mean, I think it’s it’s the field is really very different and and moving, moving very rapidly. I think the, the first line, recurrent metastatic setting is really going to probably change over the next few years from single agent, pembro or pembrolizumab and chemotherapy because of the novel agents that we mentioned. I think the question of, you know, building on the EGFR resistance with the cetuximab trials is very interesting. And, you know, more, more and more agents are basically being developed to to overcome this this mechanism and and look forward to to that also resulting in changing the standard of care. In addition to all the research around HPV related disease and the specific therapeutics that we’re seeing as well.
Read more...
